drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.
|Published (Last):||19 February 2017|
|PDF File Size:||7.79 Mb|
|ePub File Size:||6.78 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clinical practice guidelines suggest caspofungin as an alternative to posaconazole for aspergillosis prophylaxis in high-risk patients i.
Also recommended in patients with substantial risk of invasive candidiasis, such as allogeneic hematopoietic stem cell transplant HSCT recipients or those undergoing intensive remission-induction or salvage-induction chemotherapy for acute leukemia, and in patients with previous invasive aspergillosis, anticipated prolonged neutropenic periods of at least 2 weeks, or a prolonged period of neutropenia immediately prior to HSCT.
In murine models, caspofungin has been shown to have less activity against histoplasmosis than amphotericin B. Caspofungin is fungicidal against Candida sp. For infected cardiac hardware, treat for at least 4 to 6 weeks after hardware removal.
Activity in vitro Caspofungin has been shown to be active both in vitro and in clinical infections against most strains of the following microorganisms:. Limited safety data suggest that an increase in dose to 70 mg daily is well tolerated.
Caspofungin should be used in pregnancy only when the benefits clearly outweigh the risks. There have been no well-controlled studies in pregnant women.
Monitor potentially exposed infants for gastrointestinal adverse events and signs of histamine release.
Cancidas (caspofungin acetate) dose, indications, adverse effects, interactions from
Ophthalmological examination is recommended for all patients. Oral antifungal agents e.
Drugs that may lead to reductions in caspofungin concentrations include dexamethasone. Empirical therapy should be continued until neutropenia resolution.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi
Coadministration of caspofungin with CYP enzyme inducers, such as the rifamycins, results in reduced caspofungin packave concentrations. Measure potassium concentrations at baseline and periodically during dichlorphenamide treatment. For the treatment of Aspergillus pneumonia and pleural space infections in patients who are refractory to or intolerant of other antifungal therapies.
For the treatment of Aspergillus cardiovascular system infections in patients who are refractory to or intolerant of other antifungal therapies. For empirical therapy for presumed fungal infection in patients with febrile neutropenia. Treatment for at least 14 days and for at least 7 days after neutropenia and symptoms resolve is recommended for patients found to have a fungal infection. Recipient’s Email Separate multiple email canxidas with a comma Please enter valid email address Recipient’s email is required.
Cholestasis, hepatic disease, hepatitis, jaundice. Caspofungin does not interact substantially with the cytochrome P enzyme system, but does undergo significant hepatic metabolism.
Caspofungin Acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients 3 months of canidas and older for: Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. Affected cytochrome P isoenzymes: Theoretically, rifabutin and rifapentine could also decrease caspofungin blood concentrations.
Caspofungin crosses the placenta in animal models and is detected in the plasma of animal fetuses. Morphologically, fungi hyphae and yeast shapes are altered. It has no activity against Cryptococcus neoformans, but in vitro has shown synergistic activity against C.
Major If rifampin and caspofungin are administered together in adult patients, the manufacturer recommends increasing the dose of caspofungin to 70 mg daily.
Successful treatment of invasive candidiasis has been reported in neonates and young infants; however, available data are limited to small case series and studies. Surgery alone may be used to treat Aspergillus fungal ball of the paranasal sinus. Administering inducers of hepatic cytochrome P, such as nevirapine, concurrently with caspofungin may reduce the plasma concentrations of caspofungin.
Caspofungin can cause abnormalities in liver enzymes. Your email has been sent.
Although an increase in efficacy with 70 mg daily has not been demonstrated, limited safety data suggest that an increase in dose to 70 mg daily is well tolerated. Caution is advised when administering to nursing mothers. Consider intravascular catheter removal. Growth of Candida sp. Supplemental dosing is not required following hemodialysis. A short alpha-phase is followed by a beta-phase half-life of 9—11 hours ; once daily dosing is adequate.
Data are limited regarding use of caspofungin during breast-feeding and it is not known if it is excreted into human milk. Cyclosporine concentrations are not altered by coadministration with caspofungin. Dosage adjustment information is only available for adults.